Amyloid beta-protein inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Amyloid Beta-Protein Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Amyloid Beta-Protein Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Amyloid Beta-Protein Inhibitors: Overview
Amyloid-? (A?) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of theamyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield A?. Amyloid-? molecules can aggregate to form flexible soluble oligomers which may exist in several forms. Amyloid-? peptide is due to overproduction of A? and/or the failure of clearance mechanisms. Amyloid-? self-aggregates into oligomers, which can be of various sizes, and forms diffuse and neuritic plaques in the parenchyma and blood vessels.
Function – The progressive production and subsequent accumulation of ?-amyloid (A?), a proteolytic fragment of the membrane-associated amyloid precursor protein (APP), plays a central role in Alzheimer's disease (AD). A? is released in a soluble form that may be responsible for cognitive dysfunction in the early stages of the disease, then progressively forms oligomeric, multimeric and fibrillar aggregates, triggering neurodegeneration. Eventually, the aggregation and accumulation of A? culminates with the formation of extracellular plaques, one of the morphological hallmarks of the disease, detectable post-mortem in AD brains.
Amyloid Beta-Protein Inhibitors- Inhibition of the formation of these toxic polymers of A? has thus emerged as an approach to developing therapeutics for AD. Therefore, blocking the initial stages of A? peptide aggregation with small molecules could hold considerable promise as the starting point for the development of new therapies for AD.
Amyloid Beta-Protein Inhibitors Emerging Drugs Chapters
This segment of the Amyloid Beta-Protein Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Amyloid Beta-Protein Inhibitors Emerging Drugs
Further product details are provided in the report……..
Amyloid Beta-Protein Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Amyloid Beta-Protein Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Amyloid Beta-Protein Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Amyloid Beta-Protein Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Amyloid Beta-Protein Inhibitors drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Amyloid Beta-Protein Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Amyloid Beta-Protein Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Amyloid Beta-Protein Inhibitors: Overview
Amyloid-? (A?) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of theamyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield A?. Amyloid-? molecules can aggregate to form flexible soluble oligomers which may exist in several forms. Amyloid-? peptide is due to overproduction of A? and/or the failure of clearance mechanisms. Amyloid-? self-aggregates into oligomers, which can be of various sizes, and forms diffuse and neuritic plaques in the parenchyma and blood vessels.
Function – The progressive production and subsequent accumulation of ?-amyloid (A?), a proteolytic fragment of the membrane-associated amyloid precursor protein (APP), plays a central role in Alzheimer's disease (AD). A? is released in a soluble form that may be responsible for cognitive dysfunction in the early stages of the disease, then progressively forms oligomeric, multimeric and fibrillar aggregates, triggering neurodegeneration. Eventually, the aggregation and accumulation of A? culminates with the formation of extracellular plaques, one of the morphological hallmarks of the disease, detectable post-mortem in AD brains.
Amyloid Beta-Protein Inhibitors- Inhibition of the formation of these toxic polymers of A? has thus emerged as an approach to developing therapeutics for AD. Therefore, blocking the initial stages of A? peptide aggregation with small molecules could hold considerable promise as the starting point for the development of new therapies for AD.
Amyloid Beta-Protein Inhibitors Emerging Drugs Chapters
This segment of the Amyloid Beta-Protein Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Amyloid Beta-Protein Inhibitors Emerging Drugs
- Aducanumab: Biogen
- Crenezumab: Hoffman-La-Roche
Further product details are provided in the report……..
Amyloid Beta-Protein Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Amyloid Beta-Protein Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Amyloid Beta-Protein Inhibitors
- Phases
- Late-stage products (Phase III )
- Mid-stage products (Phase II )
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intravenous
- Intramuscular
- Oral
- Parenteral
- Subcutaneous
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Amyloid Beta-Protein Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Amyloid Beta-Protein Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Amyloid Beta-Protein Inhibitors drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Amyloid Beta-Protein Inhibitors R&D.
- The therapies under development are focused on novel approaches for Amyloid Beta-Protein Inhibitors.
- Amyloid Beta-Protein Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Amyloid Beta-Protein Inhibitors drugs?
- How many Amyloid Beta-Protein Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Amyloid Beta-Protein Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Amyloid Beta-Protein Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Amyloid Beta-Protein Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Amyloid Beta-Protein Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Amyloid Beta-Protein Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Amyloid Beta-Protein Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Amyloid Beta-Protein Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
late Stage Products (Preregistration)
Comparative Analysis
Aducanumab: Biogen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
R-phenserine: Annovis Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Fol PRI 002: Priavoid
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Amyloid Beta-Protein Inhibitors Key Companies
Amyloid Beta-Protein Inhibitors Key Products
Amyloid Beta-Protein Inhibitors- Unmet Needs
Amyloid Beta-Protein Inhibitors- Market Drivers and Barriers
Amyloid Beta-Protein Inhibitors- Future Perspectives and Conclusion
Amyloid Beta-Protein Inhibitors Analyst Views
Amyloid Beta-Protein Inhibitors Key Companies
Appendix
Executive Summary
Amyloid Beta-Protein Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Amyloid Beta-Protein Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Amyloid Beta-Protein Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Amyloid Beta-Protein Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
late Stage Products (Preregistration)
Comparative Analysis
Aducanumab: Biogen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
R-phenserine: Annovis Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Fol PRI 002: Priavoid
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Amyloid Beta-Protein Inhibitors Key Companies
Amyloid Beta-Protein Inhibitors Key Products
Amyloid Beta-Protein Inhibitors- Unmet Needs
Amyloid Beta-Protein Inhibitors- Market Drivers and Barriers
Amyloid Beta-Protein Inhibitors- Future Perspectives and Conclusion
Amyloid Beta-Protein Inhibitors Analyst Views
Amyloid Beta-Protein Inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Amyloid Beta-Protein Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Amyloid Beta-Protein Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Amyloid Beta-Protein Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Amyloid Beta-Protein Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products